reuters.com · 21 jul

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, ​supporting regulatory filings for what could become the first ‌regimen of its kind for the disease.

247wallst.com · 21 jul

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More

Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.

defenseworld.net · 21 jul

Andra AP fonden Has $31.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Andra AP fonden decreased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 53.9% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 222,601 shares of the biopharmaceutical company's stock after selling 260,199 shares during the period. Andra AP fonden's holdings in Gilead Sciences were

defenseworld.net · 20 jul

Dimensional Fund Advisors LP Lowers Stock Holdings in Gilead Sciences, Inc. $GILD

Dimensional Fund Advisors LP reduced its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 12.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,722,929 shares of the biopharmaceutical company's stock after selling 1,123,384 shares during the

defenseworld.net · 20 jul

Boston Common Asset Management LLC Has $10.77 Million Position in Gilead Sciences, Inc. $GILD

Boston Common Asset Management LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 8.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,243 shares of the biopharmaceutical company's stock after selling 7,238 shares during the quarter.

defenseworld.net · 19 jul

Gilead Sciences, Inc. $GILD Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 1.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 357,901 shares of the biopharmaceutical company's stock after selling 5,662 shares during the

zacks.com · 17 jul

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.

zacks.com · 16 jul

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.